2QK Stock Overview
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.90 |
| 52 Week High | US$18.30 |
| 52 Week Low | US$5.35 |
| Beta | 0.89 |
| 1 Month Change | -1.42% |
| 3 Month Change | 1.46% |
| 1 Year Change | 105.93% |
| 3 Year Change | -42.56% |
| 5 Year Change | n/a |
| Change since IPO | 47.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.6% | 2.1% | -1.0% |
| 1Y | 105.9% | -22.4% | 2.0% |
Return vs Industry: 2QK exceeded the German Biotechs industry which returned -21% over the past year.
Return vs Market: 2QK exceeded the German Market which returned 2.5% over the past year.
Price Volatility
| 2QK volatility | |
|---|---|
| 2QK Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2QK has not had significant price volatility in the past 3 months.
Volatility Over Time: 2QK's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 150 | Jay Backstrom | scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation Fundamentals Summary
| 2QK fundamental statistics | |
|---|---|
| Market cap | €1.12b |
| Earnings (TTM) | -€154.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs 2QK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$121.90m |
| Gross Profit | -US$121.90m |
| Other Expenses | US$43.89m |
| Earnings | -US$165.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 22.2% |
How did 2QK perform over the long term?
See historical performance and comparison